A5090932878- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Genetics and Neurodevelopmental Disorders
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- RNA modifications and cancer
- Gastric Cancer Management and Outcomes
- BRCA gene mutations in cancer
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- PI3K/AKT/mTOR signaling in cancer
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- CRISPR and Genetic Engineering
- Molecular Biology Techniques and Applications
- Fungal and yeast genetics research
- Legume Nitrogen Fixing Symbiosis
- Cancer survivorship and care
- Music Therapy and Health
- Colorectal Cancer Screening and Detection
- Lung Cancer Diagnosis and Treatment
- RNA and protein synthesis mechanisms
- Health and Medical Research Impacts
- Hidradenitis Suppurativa and Treatments
University Hospital of Wales
2014-2023
Great Ormond Street Hospital
2022
University College London
2022
North Bristol NHS Trust
2019-2022
Bristol Robotics Laboratory
2021-2022
Velindre Cancer Centre
2012-2021
Genomics (United Kingdom)
2021
Genomics England
2021
Glan Clwyd Hospital
2020
Dana-Farber Brigham Cancer Center
2020
Journal Article A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clones Get access J. Riley, Riley ICI Pharmaceuticals, Biotechnology DepartmentMereside, Alderley park, Macclesfield, Cheshire SK10 4TG, UK Search other works by this author on: Oxford Academic PubMed Google Scholar R. Butler, Butler D. Ogilvie, Ogilvie Finniear, Finniear Jenner, Jenner S. Powell, Powell Anand, Anand J.C. Smith, Smith A.F. Markham Nucleic Acids Research,...
Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms the serine/threonine kinase AKT. The FAKTION trial investigated whether addition capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.
Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The benefit appeared be independent of the phosphoinositide 3-kinase (PI3K)/AKT/phosphatase and tensin homologue (PTEN) pathway alteration status tumours, as ascertained using assays available at time. Here, we report updated overall results, a prespecified...
Previous studies reported that a 2- to 3-week course of IV cyclophosphamide plus adrenocorticotropic hormone (ACTH) induction can temporarily halt progressive MS for period 12 months in the majority patients treated, after which reprogression occurs. The Northeast Cooperative Multiple Sclerosis Treatment Group was formed determine whether outpatient pulse therapy could affect and there were differences between modified regimen previously published regimen. Two hundred fifty-six randomized...
The construction of a yeast artifical chromosome (YAC) primary gridded library 35,000 clones from human lymphoblastoid (48,XXXX) cell line DNA is described. average YAC size ∼350kb representing >3.5 times coverage the genme. stored at −70°C as on nylon filters impregnated with 20% glycerol and suspensions individual in microtitre plates providing prolonged multi-user potential. To date we have used 14 single copy probes to screen this by colony hybridisation well PCR isolated between 1 5 for...
Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. However, how best to minimise the time spent taking whether molecular selection can refine this further unknown. The primary aim study was establish cetuximab might be safely effectively added intermittent chemotherapy.
Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope this practice has been recently extended because data indicating that NRAS and additional also predict poor response anti-EGFR therapy. following document provides guidance on RAS (i.e., ) testing CRC setting personalised medicine within UK particularly NHS. This covers issues related case selection,...
PURPOSE Outcomes in RAS-mutant metastatic colorectal cancer (mCRC) remain poor and patients have limited therapeutic options. Adavosertib is the first small-molecule inhibitor of WEE1 kinase. We hypothesized that aberrations DNA replication seen mCRC with both RAS TP53 mutations would sensitize tumors to inhibition. METHODS Patients newly diagnosed were registered into FOCUS4 tested for mutations. Those who stable or responding after 16 weeks chemotherapy randomly assigned 2:1 between...
BackgroundA substantial change in trial methodology for solid tumours has taken place, response to increased understanding of cancer biology. FOCUS4 is a phase 2–3 programme testing targeted agents patients with advanced colorectal molecularly stratified cohorts. Here, we aimed test the hypothesis that combined inhibition EGFR, HER2, and HER3 signalling tyrosine kinase inhibitor AZD8931 will control growth all wild-type tumours.MethodsIn FOCUS4-D, included from 18 hospitals UK newly...
MECP2 mutations are responsible for Rett syndrome (RTT). Approximately a quarter of classic RTT cases, however, do not have an identifiable mutation the gene. We hypothesized that larger deletions arising from deletion prone region (DPR) occur commonly and being routinely detected by current PCR-mediated screening strategies. developed applied quantitative PCR strategy (qPCR) to samples referred diagnostic assessment 140 patients among whom was strongly suspected second selected group 31...
Journal Article Isolation of cDNA clones using yeast artificial chromosome probes Get access P. Elvin, Elvin * Department Biotechnology, ICI Pharmaceuticals, Alderley ParkMacclesfield, Cheshire SK 10 4TG, UK To whom correspondence should be addressed Search for other works by this author on: Oxford Academic PubMed Google Scholar G. Slynn, Slynn D. Black, Black A. Graham, Graham R. Butler, Butler J. Riley, Riley Anand, Anand A.F. Markham Nucleic Acids Research, Volume 18, Issue 13, 11 July...
Molecular analysis of circulating tumour DNA (ctDNA) is becoming increasingly important in clinical treatment decisions. A pilot External Quality Assessment (EQA) scheme for ctDNA was organized by four European EQA providers under the umbrella organization IQN Path, order to investigate feasibility delivering an assess detection clinically relevant variants plasma cell-free (cfDNA) and analyze reporting formats.Thirty-two experienced laboratories received 5 samples EGFR mutation and/or KRAS...
1005 Background: The PI3K/AKT signalling pathway is frequently activated in patients (pts) with estrogen receptor (ER) positive breast cancer (ER+BC) and has been implicated endocrine therapy resistance. Capivasertib (AZD5363) a highly-selective, oral, small molecule AKT inhibitor. FAKTION trial investigated the addition of capivasertib to fulvestrant for postmenopausal women ER+ HER2 negative BC after relapse or disease progression on an aromatase inhibitor (AI). Methods: investigator-led,...
Background: Complex innovative design trials are becoming increasingly common and offer potential for improving patient outcomes in a faster time frame. FOCUS4 was the first molecularly stratified trial metastatic colorectal cancer it remains one of umbrella designs to be launched globally. Here, we aim describe lessons learned from delivery over last 10 years. Methods: Phase II/III testing safety efficacy targeted therapies cancer. It used adaptive statistical methodology decide which...
Mutation detection accuracy has been described extensively; however, it is surprising that pre-PCR processing of formalin-fixed paraffin-embedded (FFPE) samples not systematically assessed in clinical context. We designed a RING trial to (i) investigate variability, (ii) correlate variation with EGFR/BRAF mutation testing and (iii) causes for observed variation.13 molecular pathology laboratories were recruited. 104 blinded FFPE curls including engineered curls, cell-negative control tissue...
Liquid biopsy testing is a new laboratory-based method that detects tumour mutations in circulating free DNA (cfDNA) derived from minimally invasive blood sampling techniques. Recognising the significance for clinical testing, 2017, IQN Path provided external quality assessment liquid testing. Representatives of those participating laboratories were invited to attend workshop discuss findings and how achieve implementation cfDNA setting, discussion outcomes this consensus meeting are...
Abstract Background Art therapy may improve the physical, mental, and emotional wellbeing of individuals for a variety purposes. It remains understudied underutilized in cancer care. We sought to determine ability pilot art program well-being patients. Methods Chemotherapy-recipients, age 18 years older, diagnosed with any type or stage cancer, were considered eligible participate this single arm, study, using four visual analog scales (VAS) visually-similar, 0–10 scale (10 being worst)...
The clinical need to determine the presence of epidermal growth factor receptor (EGFR) gene mutations in non-small-cell lung cancers (NSCLC) order make informed decisions for patient treatment has seen widespread introduction EGFR molecular testing many laboratories. To ensure high-quality and allow laboratories externally measure standard service, an external quality assessment (EQA) scheme was provided assess whole process.Formalin-fixed paraffin-embedded NSCLC tumour sections were...